Strides Pharma Science through its subsidiary has received USFDA approval for Ethosuximide Softgel capsules prescribed as an anti-epileptic medication. The drug is a generic version of Zarontin Capsules, 250 mg marketed by Pfizer.
According to market estimates, the US market for Ethosuximide Softgel Capsules USP, 250 mg, is approximately $10 million.
Company Profile : Strides Pharma Science Ltd
Leave a Reply